Journal article

Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells

Ruian Ke, Sharon R Lewin, Julian H Elliott, Alan S Perelson

PLOS PATHOGENS | PUBLIC LIBRARY SCIENCE | Published : 2015

University of Melbourne Researchers

Grants

Awarded by U.S. Department of Energy


Awarded by NIH


Awarded by NHMRC


Awarded by National Institutes of Health Delaney AIDS Research Enterprise (DARE) to find a cure


Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES


Awarded by OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH


Funding Acknowledgements

This work was performed under the auspices of the U.S. Department of Energy under contract DE-AC52-06NA25396 and supported by NIH grants R01-AI028433, R01-OD011095 and UM1-AI100645 (ASP). SRL is an NHMRC Practitioner Fellow. This work was also supported by NHMRC project grants # 4911954 and # 1002671 and the National Institutes of Health Delaney AIDS Research Enterprise (DARE) to find a cure U19 AI096109. The clinical study of vorinostat was supported in part by a research grant from the Investigator Initiated Studies Program of Merck Sharp & Dohme Corp. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.